UK health advisers have recommended free MenB vaccines for teenagers aged 15 and older, driven by a meningococcal outbreak in Kent that claimed two lives earlier this year. The Joint Committee on Vaccination and Immunisation (JCVI) flagged the serogroup B strain as a persistent public health concern among young people.
The outbreak triggered urgent reviews of vaccination coverage across the country. MenB, caused by Neisseria meningitidis serogroup B, remains one of the most aggressive forms of bacterial meningitis, with rapid progression and high mortality rates. The Kent cases exposed vulnerabilities in current immunisation schedules, which currently offer MenB jabs only to infants under one year old as part of routine childhood programs.
Extending the vaccine to teenagers addresses a protection gap in older adolescents, who face elevated transmission risk through close contact in schools and social settings. The recommendation aligns with practices in other European countries, where MenB vaccination for teenagers has become standard protocol. France and Spain already offer subsidised or free MenB vaccines to adolescents.
If implemented, the programme would represent a significant shift in UK immunisation strategy. Cost-benefit analyses will determine whether the government adopts the recommendation, though public health bodies have emphasized that the outbreak severity justifies the investment. The JCVI's advisory status carries weight with the Department of Health, though final approval requires government sign-off and budget allocation.
The move reflects growing recognition that meningococcal disease prevention requires layered protection across age groups. Current vaccine uptake data shows variable coverage among young adults, particularly those aged 15-25 who completed childhood programs before MenB became routine. Implementing free vaccination at 15 would capture a cohort with incomplete historical protection and approaching higher-risk university years.